FORM PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. P28506

Application No. 10/550,013

Applicant

JUN 1 8 2008

INFORMATION DISCLOSURE STATEMENT Rudolf FAHRIG et al BY APPLICANT (Use several sheets if necessary) Filing Date Group September 23, 2005 1623 **U.S. PATENT DOCUMENTS EXAMINER** FILING DATE INITIAL DATE NAME **SUBCLASS** IF APPROPRIATE DOCUMENT NUMBER CLASS FOREIGN PATENT DOCUMENTS **TRANSLATION** DOCUMENT NUMBER DATE **COUNTRY CLASS SUBCLASS** YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1 Fahrig et al., RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients, Anti-Cancer Drugs 2006, 17:1045-1056. 2 Fahrig et al., Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (RP101), Cancer Research 63, 5745-5753, September 15, 2003. 3 U.S. Patent Application 11/853,540, filed September 11, 2007.

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.